HIV Citations List: September, 2016

Literature Citations

1. Fragment-based Discovery of a New Family of Non-peptidic Small-molecule Cyclophilin Inhibitors with Potent Antiviral Activities. Ahmed-Belkacem, A., L. Colliandre, N. Ahnou, Q. Nevers, M. Gelin, Y. Bessin, R. Brillet, O. Cala, D. Douguet, W. Bourguet, I. Krimm, J.M. Pawlotsky, and J.F. Guichou. Nature Communications, 2016. 7(12777): 11pp. PMID[27652979]. PMCID [PMC5036131].
[PubMed]. HIV_09_2016.

2. Production of a Highly Potent Epoxide through the Microbial Metabolism of 3-Acetoxyurs-11-en-13,28-olide by Aspergillus niger Culture. Ali, S., M. Nisar, and H. Gulab. Pharmaceutical Biology, 2016. 54(9): p. 1942-1946. PMID[26736075].
[PubMed]. HIV_09_2016.

3. Covalent Inhibition of HIV-1 Integrase by N-succinimidyl Peptides. Chandra, K., P. Das, S. Mamidi, M. Hurevich, A. Iosub-Amir, N. Metanis, M. Reches, and A. Friedler. ChemMedChem, 2016. 11(18): p. 1987-1994. PMID[27331774].
[PubMed]. HIV_09_2016.

4. Abacavir + Dolutegravir + Lamivudine for the Treatment of HIV. Comi, L. and F. Maggiolo. Expert Opinion in Pharmacotherapy, 2016. 17(15): p. 2097-2106. PMID[27616133].
[PubMed]. HIV_09_2016.

5. Rational Design, Synthesis and Evaluation of Coumarin Derivatives as Protein-Protein Interaction Inhibitors. De Luca, L., F.E. Agharbaoui, R. Gitto, M.R. Buemi, F. Christ, Z. Debyser, and S. Ferro. Molecular Informatics, 2016. 35(8-9): p. 460-473. PMID[27546050].
[PubMed]. HIV_09_2016.

6. Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs. Fader, L.D., M. Bailey, E. Beaulieu, F. Bilodeau, P. Bonneau, Y. Bousquet, R.J. Carson, C. Chabot, R. Coulombe, J.M. Duan, C. Fenwick, M. Garneau, T. Halmos, A. Jakalian, C. James, S.H. Kawai, S. Landry, S.R. LaPlante, S.W. Mason, S. Morin, N. Rioux, B. Simoneau, S. Surprenant, B. Thavonekham, C. Thibeault, T. Trinh, Y. Tsantrizos, J. Tsoung, C. Yoakim, and D. Wernic. ACS Medicinal Chemistry Letters, 2016. 7(8): p. 797-801. PMID[27563405]. PMCID[PMC4983734].
[PubMed]. HIV_09_2016.

7. Activity of Phosphino Palladium(II) and Platinum(II) Complexes against HIV-1 and Mycobacterium Tuberculosis. Gama, N.H., A.Y.F. Elkhadir, B.G. Gordhan, B.D. Kana, J. Darkwa, and D. Meyer. Biometals, 2016. 29(4): p. 637-650. ISI[000381144200006].
[WOS]. HIV_09_2016.

8. Discovery of Novel anti-HIV Agents via Cu(I)-catalyzed Azide-alkyne Cycloaddition (CuAAC) Click Chemistry-based Approach. Gao, P., L. Sun, J. Zhou, X. Li, P. Zhan, and X. Liu. Expert Opinion on Drug Discovery, 2016. 11(9): p. 857-871. PMID[27400283].
[PubMed]. HIV_09_2016.

9. Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency. Geng, G., B. Liu, C. Chen, K. Wu, J. Liu, Y. Zhang, T. Pan, J. Li, Y. Yin, J. Zhang, F. Huang, F. Yu, J. Chen, X. Ma, J. Zhou, E. Kuang, C. Liu, W. Cai, and H. Zhang. Molecular Therapy, 2016. 24(9): p. 1528-1537. PMID[27434587].
[PubMed]. HIV_09_2016.

10. Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. Kang, D., Z. Fang, Z. Li, B. Huang, H. Zhang, X. Lu, H. Xu, Z. Zhou, X. Ding, D. Daelemans, E. De Clercq, C. Pannecouque, P. Zhan, and X. Liu. Journal of Medicinal Chemistry, 2016. 59(17): p. 7991-8007. PMID[27541578].
[PubMed]. HIV_09_2016.

11. Design, Synthesis, and Biological Evaluation of Novel 5-Alkyl-6-adamantylmethylpyrimidin-4(3H)-ones as HIV-1 Non-Nucleoside Reverse-Transcriptase Inhibitors. Li, W., B. Huang, D. Kang, E. De Clercq, D. Daelemans, C. Pannecouque, P. Zhan, and X. Liu. Chemical Biology & Drug Design, 2016. 88(3): p. 380-385. PMID[27062197].
[PubMed]. HIV_09_2016.

12. Synthesis and anti-HIV-1 Activity Evaluation for Novel 3a,6a-Dihydro-1H-pyrrolo[3,4-c]pyrazole-4,6-dione Derivatives. Liu, G.N., R.H. Luo, Y. Zhou, X.J. Zhang, J. Li, L.M. Yang, Y.T. Zheng, and H. Liu. Molecules, 2016. 21(9): p. E1198. PMID[27617994].
[PubMed]. HIV_09_2016.

13. Glycosyl Phosphatidylinositol-anchored C34 Peptide Derived from Human Immunodeficiency Virus Type 1 Gp41 Is a Potent Entry Inhibitor. Liu, L., M. Wen, Q. Zhu, J.T. Kimata, and P. Zhou. Journal of Neuroimmune Pharmacology, 2016. 11(3): p. 601-610. PMID[27155865].
[PubMed]. HIV_09_2016.

14. Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of Novel Purinylthioacetanilides Derivatives as Potent HIV-1 NNRTIs via a Structure-based Bioisosterism Approach. Lu, X., X. Li, J. Yang, B. Huang, D. Kang, F. Zhao, Z. Zhou, E. De Clercq, D. Daelemans, C. Pannecouque, P. Zhan, and X. Liu. Bioorganic & Medicinal Chemistry, 2016. 24(18): p. 4424-4433. PMID[27501911].
[PubMed]. HIV_09_2016.

15. Fullerene Derivatives Strongly Inhibit HIV-1 Replication by Affecting Virus Maturation without Impairing Protease Activity. Martinez, Z.S., E. Castro, C.S. Seong, M.R. Ceron, L. Echegoyen, and M. Llano. Antimicrobial Agents and Chemotherapy, 2016. 60(10): p. 5731-5741. PMID[27431232]. [PubMed]. HIV_09_2016.

16. Linear Biocompatible Glyco-polyamidoamines as Dual Action Mode Virus Infection Inhibitors with Potential as Broad-spectrum Microbicides for Sexually Transmitted Diseases. Mauro, N., P. Ferruti, E. Ranucci, A. Manfredi, A. Berzi, M. Clerici, V. Cagno, D. Lembo, A. Palmioli, and S. Sattin. Scientific Reports, 2016. 6(33393): 8pp. PMID[27641362]. PMCID[PMC5027566].
[PubMed]. HIV_09_2016.

17. Novel Acylguanidine-based Inhibitor of HIV-1. Mwimanzi, P., I. Tietjen, S.C. Miller, A. Shahid, K. Cobarrubias, N.N. Kinloch, B. Baraki, J. Richard, A. Finzi, D. Fedida, Z.L. Brumme, and M.A. Brockman. Journal of Virology, 2016. 90(20): p. 9495-9508. PMID[27512074].
[PubMed]. HIV_09_2016.

18. Structural Basis of HIV Inhibition by Translocation-defective RT Inhibitor 4 '-Ethynyl-2-fluoro-2 '-deoxyadenosine (EFdA). Salie, Z.L., K.A. Kirby, E. Michailidis, B. Marchand, K. Singh, L.C. Rohan, E.N. Kodama, H. Mitsuya, M.A. Parniak, and S.G. Sarafianos. Proceedings of the National Academy of Sciences of the United States of America, 2016. 113(33): p. 9274-9279.PMID[27489345]. PMCID[PMC4995989].

[PubMed]. HIV_09_2016.

19. Pyrazolo[1,5-a]pyrimidine-based Macrocycles as Novel HIV-1 Inhibitors: A Patent Evaluation of WO2015123182. Sun, L., P. Gao, P. Zhan, and X. Liu. Expert Opinion on Therapeutic Patents, 2016. 26(9): p. 979-986. PMID[27398994].
[PubMed]. HIV_09_2016.

20. Croton megalobotrys Mull Arg. and Vitex doniana (Sweet): Traditional Medicinal Plants in a Three-step Treatment Regimen That Inhibit in Vitro Replication of HIV-1. Tietjen, I., T. Gatonye, B.N. Ngwenya, A. Namushe, S. Simonambanga, M. Muzila, P. Mwimanzi, J. Xiao, D. Fedida, Z.L. Brumme, M.A. Brockman, and K. Andrae-Marobela. Journal of Ethnopharmacology, 2016. 191: p. 331-340. PMID[27350006].
[PubMed]. HIV_09_2016.

21. HIV Protease Inhibitors Apoptotic Effect in SH-SY5Y Neuronal Cell Line. Tricarico, P.M., R.F. de Oliveira Franca, S. Pacor, V. Ceglia, S. Crovella, and F. Celsi. Cellular Physiology and Biochemistry, 2016. 39(4): p. 1463-1470. PMID[27607424].
[PubMed]. HIV_09_2016.

22. RbAp48, a Novel Inhibitory Factor That Regulates the Transcription of Human Immunodeficiency Virus Type 1. Wang, J., J. Yang, Z.X. Yang, X.Y. Lu, C.Z. Jin, L.F. Cheng, and N.P. Wu. International Journal of Molecular Medicine, 2016. 38(1): p. 267-274. PMID[27222146].

[PubMed]. HIV_09_2016.

23. M2BP Inhibits HIV-1 Virion Production in a Vimentin Filaments-dependent Manner. Wang, Q., X.L. Zhang, Y.L. Han, X.L. Wang, and G.X. Gao. Scientific Reports, 2016. 6(32736): 14pp. PMID[27604950]. PMCID[PMC5015019].

[PubMed]. HIV_09_2016.

24. Zinc-stabilized Chitosan-chondroitin sulfate Nanocomplexes for HIV-1 Infection Inhibition Application. Wu, D., A. Ensinas, B. Verrier, C. Primard, A. Cuvillier, G. Champier, S. Paul, and T. Delair. Molecular Pharmaceutics, 2016. 13(9): p. 3279-3291. PMID[27454202].
[PubMed]. HIV_09_2016.

25. Synthesis of Pyrazine-1,3-thiazine Hybrid Analogues as Antiviral Agent against HIV-1, Influenza a (H1N1), Enterovirus 71 (Ev71), and Coxsackievirus B3 (CVB3). Wu, H.M., K. Zhou, T. Wu, and Y.G. Cao. Chemical Biology & Drug Design, 2016. 88(3): p. 411-421. PMID[27062664].
[PubMed]. HIV_09_2016.

26. Discovery of HIV Type1 Aspartic Protease Hit Compounds through Combined Computational Approaches. Xanthopoulos, D., E. Kritsi, C.T. Supuran, M.G. Papadopoulos, G. Leonis, and P. Zoumpoulakis. ChemMedChem, 2016. 11(15): p. 1646-1652. PMID[27411556].
[PubMed]. HIV_09_2016.

27. Design, Synthesis and anti-HIV Evaluation of Novel Diarylpyridine Derivatives Targeting the Entrance Channel of NNRTI Binding Pocket. Yang, J.P., W.M. Chen, D.W. Kang, X.Y. Lu, X. Li, Z.Q. Liu, B.S. Huang, D. Daelemans, C. Pannecouque, E. De Clercq, P. Zhan, and X.Y. Liu. European Journal of Medicinal Chemistry, 2016. 109: p. 294-304. PMID[26802545].
[PubMed]. HIV_09_2016.

28. Data on Synthesis of Methylene bisphosphonates and Screening of Their Inhibitory Activity Towards HIV Reverse Transcriptase. Yanvarev, D.V., A.N. Korovina, N.N. Usanov, O.A. Khomich, J. Vepsalainen, E. Puljula, M.K. Kukhanova, and S.N. Kochetkov. Data in Brief, 2016. 8: p. 1157-1167. PMID[27547792]. PMC4978200[PMC4978200].
[PubMed]. HIV_09_2016.

29. Ribosome-inactivating Proteins from Root Tubers and Seeds of Trichosan-thes kirilowii and Other Trichosanthes Species. Ye, X.J., C.C.W. Ng, J.H. Wong, T.B. Ng, G.H.H. Chan, S.Z. Guan, and O. Sha. Protein and Peptide Letters, 2016. 23(8): p. 699-706. PMID[27225069].
[PubMed]. HIV_09_2016.

30. Venom Components of Iranian Scorpion Hemiscorpius lepturus Inhibit the Growth and Replication of Human Immunodeficiency Virus 1 (HIV-1). Zabihollahi, R., K. Pooshang Bagheri, Z. Keshavarz, F. Motevalli, G. Bahramali, S.D. Siadat, S.B. Momen, D. Shahbazzadeh, and M.R. Aghasadeghi. Iran Biomed J, 2016. 20(5): p. 259-265. PMID[27594443].
[PubMed]. HIV_09_2016.

31. Rational Improvement of Gp41-targeting HIV-1 Fusion Inhibitors: An Innovatively Designed Ile-Asp-Leu Tail with Alternative Conformations. Zhu, Y., S. Su, L. Qin, Q. Wang, L. Shi, Z. Ma, J. Tang, S. Jiang, L. Lu, S. Ye, and R. Zhang. Scientific Reports, 2016. 6(31983): 9pp. PMID[27666394]. PMCID[PMC5036048].
[PubMed]. HIV_09_2016.

Patent Citations

32. Preparation of Triazole and Tetrazole Inhibitors of Human DDX3 Helicase as Antiviral Therapeutic Agents. Meyerhans, A., M.-A. Martinez de la Sierra, A. Brai, R. Fazi, C. Tintori, M. Botta, J.-E. Araque, and J. Martinez. Patent. 2016. 2016-EP52990 2016128541: 174pp.

[Patent]. HIV_09_2016.

33. Griffithsin Mutants. O'Keefe, B.R., T. Moulaei, K.E. Palmer, L.C. Rohan, and J.L. Fuqua. Patent. 2016. 2016-US17267 2016130628: 32pp.

[Patent]. HIV_09_2016.

34. Quinoline Derivatives for Use in the Treatment or Prevention of Viral Infection, in Particular HIV Infection. Scherrer, D., A. Garcel, N. Campos, J. Tazi, A. Vautrin, F. Mahuteau-Betzer, R. Najman, and P. Fornarelli. Patent. 2016. 2015-305277 3058940: 39pp.

[Patent]. HIV_09_2016.

35. Compositions and Methods for Inhibiting Viral Infection by Administering AR-12 and Its Analogs. Schlesinger, L., J. Yount, A. Zukiwski, S. Proniuk, M.J. Tunon, and K. Zandi. Patent. 2016. 2016-15008306 20160213647: 43pp.

[Patent]. HIV_09_2016.

36. Small Molecules Targeting HIV-1 Nef. Smithgall, T.E. Patent. 2016. 2016-15042069 20160235750: 16pp.

[Patent]. HIV_09_2016.